Canadian grants & funding programs

World Trade Center Health Program Mentored Research Scientist Career Development Award (K01)

The purpose of the World Trade Center (WTC) Health Program Mentored Research Scientist Career Development Award (K01) is to provide support and 75% ‚Äúprotected time‚Äů for an intensive, supervised (mentored) career development experience in WTC-related health research. This can facilitate the transition of junior research scientists from the mentored to the independent stages of their careers in WTC-related health research. By providing support for the critical transition period between postdoctoral training and independent U01 or R01 funding for investigators, NIOSH/WTC Health Program hopes to foster the careers of these investigators, who are vital for the future excellence of WTC-related health research endeavors.NIOSH/WTC Health Program supports K01 grants to help ensure the availability of an adequate number and diversity of highly trained scientists and educators to address issues related to diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 Health and Compensation Act of 2010 (Public Law 111‚Äě347, as amended by Public Laws¬†114‚Äě113¬†and¬†116‚Äě59). Enrolled WTC responders and certified-eligible WTC survivors will be included in the research project.Applicants must justify the need for a period of mentored research experience and convincingly describe how the proposed period of support will substantially enhance their careers as independent investigators. Applicants must also concisely describe the issues related to diagnostic or treatment uncertainty addressed in their proposal. Applicants should clearly articulate the anticipated impacts of the proposed research, both during the project period and beyond.

United States

Climate-Ready Plans and Processes

60% funding for climate risk assessments, adaptation plans, training, and community engagement

Grant Goals - Develop comprehensive climate adaptation strategies - Enhance municipal climate resilience - Support proactive climate risk assessment and mitigation - Promote equitable and inclusive climate action - Build capacity for climate adaptation planning Keywords - Climate resilience - Municipal adaptation - Risk assessment - Climate hazard mitigation - Vulnerability mapping - Equity-informed planning - Adaptive infrastructure - Community engagement - Climate data analysis - Sustainable municipal development - Resilience planning - Climate change preparedness - Urban climate strategy - Adaptive governance - Inclusive climate action Description The Green Municipal Fund provides funding to support Canadian municipalities in developing comprehensive climate adaptation strategies. The program focuses on helping communities understand and mitigate climate risks through detailed assessments, planning, and capacity-building initiatives. Target Audience - Canadian municipal governments - Municipal corporations - Regional/provincial organizations delivering municipal services - Non-governmental organizations - Not-for-profit organizations - Research institutes - Indigenous communities Eligible Expenses - Climate risk assessment development - Vulnerability mapping - Climate adaptation plan creation - Community engagement strategies - Staff training and capacity building - Integration of climate adaptation into existing municipal plans - Climate hazard identification and analysis Eligibility - Must be a Canadian municipal government or eligible partner - Project must be completed within two years - Focus on climate change adaptation - Proactive approach to climate risk mitigation - Inclusive and equitable planning strategies Criteria - Addresses multiple climate hazards - Integrates with existing municipal plans - Promotes community resilience - Demonstrates measurable outcomes - Supports equity-deserving communities - Innovative approach to climate adaptation Program Requirements - Two-year project completion timeline - Comprehensive climate risk assessment - Detailed adaptation strategy - Community engagement plan - Equity and inclusion considerations - Measurable climate resilience outcomes Hiring Criteria - Climate adaptation expertise - Data analysis skills - Community engagement experience - Understanding of municipal governance - Systems thinking approach - Equity and inclusion knowledge Due Dates - Funding currently scheduled to open in 2025 - Specific application deadlines to be announced Start Dates - Projects must be completed within two years of grant approval - Exact start dates flexible within funding cycle Age Requirements - No specific age restrictions - Focus on organizational capacity and project merit Industry / Area of Work - Municipal governance - Climate adaptation - Urban planning - Infrastructure resilience - Community development - Environmental sustainability - Public policy - Climate science

Alberta · British Columbia · Manitoba · New Brunswick +9 more

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its related dementias (ADRD) that need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.

United States

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R21 Clinical Trial Optional)

The National Institute of Mental Health (NIMH) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on the dapivirine vaginal ring for HIV prevention, including research to: advance understanding of multilevel facilitators and barriers to use of the dapivirine vaginal ring; develop interventions to support uptake and correct and persistent use of the vaginal ring; and test implementation strategies for optimal delivery of the vaginal ring.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.Ôř?. The FOA is expected to be published in Winter 2022with an expected application due date in Summer 2022.. This FOA will utilize the R21Ôř? activity code, and companion FOAs will utilize the R01 (see NOT-MH-22-020) and the R34 (see NOT-MH-22-022) activity codes. Details of the planned FOA are provided below.

United States

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.

United States

Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)

Reissue of PAR-19-146 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

United States

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed)

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in Down syndrome. This initiative seeks applications that are intended to facilitate Down syndrome research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials for Down syndrome and its co-occurring conditions, and to increase their likelihood of success through development and testing of biomarkers and clinical outcome assessment measures, development and testing of novel trial methods and recruitment strategies, or by defining the presentation and course of the co-occurring conditions in individuals with Down syndrome to enable the design of future clinical trials.

United States

CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. . This FOA supports translational research that includes, but is not limited to, preliminary efficacy and/or early preclinical development studies towards discovery and validation of novel molecular entities or biologics as candidate MCMs. In addition to novel agents, new treatment strategies may involve repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action.. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement program and/or other related initiatives.

United States

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

United States

Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 Clinical Trials Not Allowed)

The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

United States

Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed)

This FOA invites applications proposing to establish new, or significantly expand existing, interdisciplinary collaborations involving both experimental and computational researchers to simultaneously address a targeted research question in brain aging and Alzheimer's disease (AD),including Alzheimer's disease related dementias (ADRD). This FOA will use the R21/R33 to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable interdisciplinary collaboration across experimental and computational laboratories to support projects that address key research questions in brain aging and AD/ADRD.

United States

Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

United States

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

United States

Understanding Chronic Conditions Understudied Among Women (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Womens Health (ORWH) and the scientific partnering Institutes and Centers across NIH.

United States

Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R21 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit developmental/exploratory research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).

United States

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)

This HEAL FOA provides an opportunity for early career researchers or early career clinicians with foundational backgrounds in addiction to develop expertise in implementation science. Successful applicants would propose training in implementation science methods, and a research project that would apply these to at least one of the four priority domains of the HHS Overdose Prevention Strategy: primary prevention (including appropriate opioid prescribing), OUD treatment, harm reduction, and/or recovery support services. The overarching goal is to build a cadre of implementation researchers who can contribute to addressing the current overdose crisis, develop research careers that will impact the quality of addiction clinical practice generally, and become the next generation of implementation experts and mentors.

United States

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects proposing the application of existing methods or algorithms where the novelty resides in the biological or clinical question being pursued are not responsive to this solicitation and will not be reviewed.

United States

Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) will support analyses of existing RADx-UP data by proposing novel questions related to SARS-CoV-2 testing and health disparities. These projects will explore important questions focused on COVID-19 testing access and uptake, factors affecting testing and related COVID-19 outcomes, and meta-analyses of specific COVID-19 response and intervention approaches within and across populations.

United States

NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)

NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.

United States

Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. For this announcement, unpublished preliminary data are limited to one figure, comprising no more than one-half page, to facilitate the entry of qualified new investigators to the field.

United States

Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

United States

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH), including exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities ( https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html; https://www.oar.nih.gov/hiv-policy-and-research/research-priorities). Research teams should contain an appropriate mix of expertise to accomplish the proposed studies, including partnerships between HIV and NCD researchers who can initiate new ideas and determine feasibility of novel approaches to understand and reduce the long-term suffering from the comorbid disorders. Applicants will also be asked to address the needs of collaborating LMIC institutions to develop capacity for carrying out research in this field. U.S. and LMIC investigators are eligible to apply for collaborative projects to be done at LMIC sites; however, a U.S. investigator must apply together with an LMIC investigator. LMICs are defined by the World Bank classification system according to Gross National Income (GNI) per capita as low-income, lower-middle-income, and upper-middle-income (http://data.worldbank.org/about/country-classifications/country-and-lending-groups).

United States

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

United States

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

United States

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

United States

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

United States

Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

United States

Mechanisms and Targets at the Intersection of HIV and Substance Use (R21 Clinical Trials Not Allowed)

The purpose of this FOA is to support basic research on signaling pathways and mechanisms including HIV-host protein interactions and post-translational modifications by which addictive drugs and HIV infection converge to induce changes in brain function and cause neuropathological alterations and neurocognitive dysfunctions. This FOA also aims to promote discovery and development of novel chemical and biological approaches for prevention or mitigation of CNS complications associated with HIV infection and substance use disorders.

United States

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); and 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service. It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).

United States

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

United States

Biology of Bladder Cancer (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

United States

Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory/development basic research projects that elucidate mechanisms by which the human microbiome inhibit or enhance anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites targets immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application.

United States

Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will solicit R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.

United States

Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.

United States

Co-infection and Cancer (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

United States

Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)

United States

NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)

The goal of this funding opportunity announcement (FOA) is to fund meritorious vision-related research projects that involve secondary data analyses using existing database resources. The development of statistical methodology necessary for improving methods to analyze vision health data using existing vision data may also be proposed.

United States

NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)

Reissue of PA-18-350. The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.

United States

Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory and innovative research applications focused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this NOFO.

United States

F23AS00339 - White-nose Syndrome Research and Conservation Grants - 2023

The U.S. Fish and Wildlife Service (Service) is pleased to announce the availability of funding in 2023 for research and conservation action to support the management of white-nose syndrome (WNS) and susceptible bat species. The Service provides financial and technical assistance to nongovernmental, university, and private researchers, as well as state and local governments, Native American tribes, and federal agencies, for the management of WNS and conservation of bats. Funded projects will investigate priority questions to improve our ability to manage the disease and implement management actions that will help to conserve affected bat species.As of April 2023, WNS is confirmed or suspected in bats in 39 states and eight Canadian provinces, and evidence of the causative fungus, Pseudogymnoascus destructans (Pd), has been detected in at least four additional states and two provinces without additional signs of the disease. Numerous North American and Eurasian species of bats have been confirmed with WNS or detected carrying Pd. For information on WNS and previously funded projects, please see: http://www.whitenosesyndrome.org/Funding through WNS Research and Conservation Grants provides critical resources for maximizing the benefits of conservation efforts for bats. These actions are focused on minimizing the impacts of WNS and compounding stressors on federally listed species, prioritizing actions to conserve species that are susceptible to the disease, including those that may be assessed for listing due to the impacts of WNS, and understanding how different species are likely to respond when exposed to the pathogen. Projects submitted to this opportunity should concentrate on efforts where there is the greatest need and benefit.Priorities for this funding opportunity are designed to develop and apply tools that maximize persistence of WNS-affected bat populations, minimize impacts from Pd, and support recovery of impacted species. Competitive projects will also support collaborative actions of the WNS National Response and inform management decisions for WNS and bats. Scientific research conducted in collaboration with management authorities is encouraged. Due to the urgency of this threat to bats and the rapid progress of related science, we seek to fund projects that are likely to produce impactful results within a two year project period.A. Objective: Assess disease dynamics and population impacts in areas on the leading edge of WNS.Priorities:Understand Pd invasion dynamics and effects of WNS on northern long-eared bat and tricolored bat in coastal and southeastern regions.Investigate mechanisms affecting rates of spread and severity of WNS in western bat populations recently or imminently exposed to Pd, including apparent regional differences.B.¬†Objective: Improve critical knowledge relevant to WNS risk and management decisions for‚ÄŘhibernating bats.‚ÄŘPriorities:Test hypothesize related to evolutionary or behavioral resistance or tolerance to WNS in WNS-affected species.of bats.Understand mechanisms affecting variability in severity of WNS among species, regions, and localities.Understand‚ÄŘeffects of‚ÄŘnon-disease‚ÄŘfactors that‚ÄŘintroduce additive‚ÄŘor compounding‚ÄŘimpacts to WNS-affected bat species (e.g. contaminants, wind energy, etc.).C. Objective: Conduct management activities aimed at building resiliency and promoting population growth in hibernating bat populations.‚ÄŘPrioritiesImplement adaptive management programs to improve survival and persistence of bat populations currently being or soon to be impacted by WNS.¬† (Management tools with ability to reach and benefit a large number of bats in at risk populations are a high priority.)Develop and implement strategies to support biological and ecological needs of hibernating bat populations, including management actions to promote resilience to climate change, invasive species and other future stressors.White-nose Syndrome Research and Conservation Grants complement three additional funding opportunities from the Service in support of the WNS National Response in 2023: 1) WNS Grants to States and Tribes 2023 (www.Grants.gov, F23AS00330); 2) Bats for the Future Fund (National Fish and Wildlife Foundation (www.nfwf.org/bats); and 3) Biotechnological Tools WNS Research for Conservation Grants-Biotechnology (www.Grants.gov, F23AS00037). Contact the Service‚Äôs WNS national assistant coordinator for more information about these funding opportunities.The use of grant funds requires adherence to established protocols and methodologies developed or espoused by the national WNS working groups for surveillance, diagnostics, population monitoring, conservation and recovery, and disease management (for more information contact the appropriate Service WNS coordinator), as well as the Endangered Species Act, National Historic Preservation Act, National Environmental Policy Act. All proposed actions must be in line with the most current guidance, policies, and information related to the COVID-19 pandemic and SARS-CoV-2.The Service‚Äôs WNS program is coordinated and funded through the branches of Ecological Services and Science Applications and grants will be administered through the Wildlife and Sport Fish Restoration program (WSFR). Grants will be competitively awarded based on merit review of proposed projects for their applicability and feasibility to address priorities identified in this notice and for their overall contribution to meeting the objectives of the WNS national plan (White-Nose Syndrome Response Plans).

United States

Pre-Retrofit Funding for multi-unit residential buildings

100% funding for energy audits, building assessments, engineering studies, and retrofit planning.

Grant Goals - Accelerate Canada's net-zero emissions target by 2050 - Support deep energy retrofits in affordable housing - Enable comprehensive building performance assessments - Facilitate sustainable housing infrastructure improvements Keywords - Energy efficiency - Sustainable housing - Retrofit funding - Climate resilience - Green infrastructure - Affordable housing - Building performance - Carbon reduction - Energy auditing - Sustainable development - Thermal optimization - Renewable energy integration - Housing innovation - Environmental assessment - Decarbonization strategies Description The Canada Greener Affordable Housing – Pre-Retrofit Funding program supports comprehensive energy performance assessments for multi-unit residential buildings. By providing up to $130,000 in contributions, the program enables housing providers to conduct critical pre-retrofit evaluations that inform deep energy retrofit strategies. Target Audience - Community housing providers - Non-profit housing organizations - Public housing agencies - Rental cooperatives - Indigenous governments and organizations - Provincial and municipal governments - First Nations - Tribal Councils - Indigenous housing providers Eligible Expenses - Building condition assessment reports - Energy audits (ASHRAE 3 or equivalent) - Energy modelling studies - Project drawings and specifications - Engineering studies - Construction cost estimates - Business case development - Environmental site assessments - Hazardous materials reports - Site surveys Eligibility - Affordable housing purpose - Proven mandate for lower-income housing - Minimum 5 residential units - Buildings minimum 20 years old - Non-residential component ≤30% of gross floor space - Mixed-income rental or mixed-use properties - Community housing - Indigenous community housing - Shelters and supportive housing - Single-room occupancy properties Criteria - Primarily residential properties - Documented housing mandate - Commitment to deep energy retrofits - Comprehensive pre-retrofit assessment - Alignment with net-zero emissions goals - Demonstrated financial need - Organizational capacity for implementation Program Requirements - Complete key pre-retrofit activities - Provide detailed project documentation - Submit quotes for proposed activities - Align with climate adaptation objectives - Demonstrate potential energy performance improvements - Prepare for subsequent retrofit funding application Hiring Criteria - Technical expertise in building assessments - Energy efficiency specialists - Engineering professionals - Environmental assessment consultants - Sustainability project managers Due Dates - Application windows of 60 days - Fiscal year alignment - Project expenses within same fiscal year as approval Start Dates - Program initiated in 2023-24 - Funding available over 3 years - Flexible project commencement based on assessment readiness Age Requirements - Buildings minimum 20 years old - Flexibility for Indigenous, Northern, or remote organizations Industry / Area of Work - Affordable housing - Sustainable infrastructure - Energy efficiency - Climate adaptation - Social housing - Community development - Green building technologies

Alberta · British Columbia · Manitoba · New Brunswick +9 more

Research on Interventions that Promote the Careers of Individuals in the Biomedical Research Enterprise (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages solicits applications that propose research designed to test training, mentoring, and networking interventions intended to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the design and implementation of potential interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.

United States

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

United States

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to either support or refute a stated hypothesis about brain function. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed.

United States

Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)

The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.

United States

OJJDP FY 2023 Juvenile Justice Emergency Planning Demonstration Program for Juvenile Justice Residential Facilities

OJP is committed to advancing work that promotes civil rights and racial equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety and protects the public from crime and evolving threats, and builds trust between law enforcement and the community. . . OJJDP's guiding philosophy is to enhance the welfare of America's youth and broaden their opportunities for a better future. To bring these goals to fruition, OJJDP is leading efforts to transform the juvenile justice system into one that will Treat Children as Children; Serve Children at Home, With Their Families, in their Communities; and Open Up Opportunities for System-Involved Youth. OJJDP encourages all proposed applications that work with youth to highlight how the proposed program aligns with these priorities. . . OJJDP envisions a juvenile justice system centered on the strengths, needs, and voices of youth and families. Young people and family members with lived experience are vital resources for understanding and reaching persons involved or at risk of involvement with youth-serving systems. OJJDP asks stakeholders to join us in sustainably integrating bold, transformative youth and family partnership strategies into our daily work. OJJDP believes in achieving positive outcomes for youth, families, and communities through meaningful engagement and active partnerships, ensuring they play a central role in collaboratively developing solutions.. . Applicants must describe how their proposed project/program will integrate and sustain meaningful youth and family partnerships into their project plan and budget. Depending on the nature of an applicant's proposed project, youth and family partnership could consist of one or more of the following:. . . Individual-level partnership in case planning and direct service delivery (before, during, and after contact with youth-serving systems).. Agency-level partnership (e.g., in policy, practice, and program development, implementation, and evaluation; staffing; advisory bodies; budget development).. System-level partnership (e.g., in strategic planning activities, system improvement initiatives, advocacy strategies, reform efforts).. . . With this solicitation, OJJDP seeks to support emergency planning for state, local, and Tribal juvenile justice residential facilities. For youth that reside in residential facilities it is crucial that applicants plan for and facilitate continued meaningful engagement with family and other supportive members of their community. Applicants are encouraged to ensure that these activities and strategies are prioritized in any emergency planning effort. Examples of ways that applicants could partner with youth and families includes establishing or utilizing an existing advisory group that includes family members of and/or youth that are currently or have previously been housed in the facility. These members could be involved in the drafting and reviewing of existing and new emergency planning procedures, to include evacuation strategies, and plans to ensure ongoing notification and communication procedures.

United States

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)

United States